ReviewFrontiers in oncology2026
AI-enabled D-dimeromics in precision breast oncology: a transformative framework for the identification, stratification, and prognostication of ultra-high-risk disease phenotypes.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a highly diverse ailment marked by various molecular subtypes, differing clinical paths, and unique treatment reactions. Notwithstanding considerable progress in precision oncology, the prompt detection of patients with ultra-high-risk breast cancer phenotypes continues to be a significant clinical hurdle. Growing evidence suggests that hypercoagulability linked to cancer and thromboinflammation are vital in tumour advancement, metastatic spread, evasion of immunity, and resistance to treatment. D-dimer has become a notable biomarker for coagulation, signalling tumour aggressiveness, disease extent, and unfavorable clinical results. Nonetheless, traditional D-dimer evaluation depends on singular assessments that do not reflect the intricate biological interactions influencing breast cancer advancement. To overcome this limitation, the idea of D-dimeromics has arisen as a comprehensive framework that combines D-dimer with additional haemostatic, inflammatory, molecular, radiological, and clinical data. Simultaneously, progress in artificial intelligence (AI), particularly in machine learning and deep learning, has facilitated the examination of high-dimensional biomedical data and the identification of predictive patterns that exceed the capabilities of conventional statistical methods. This narrative review examines the biological justifications, technological bases, and clinical uses of AI-driven D-dimeromics as a groundbreaking precision oncology approach for detecting ultra-high-risk breast cancer phenotypes. The article examined the connections between coagulation activation and tumour development, the prognostic value of D-dimer in various breast cancer subtypes, and the function of AI in combining multidimensional data for dynamic risk assessment, metastatic prediction, treatment response evaluation, and individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.